Compare BridgeBio Pharma Inc (BBIO) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Koninklijke Philips NV — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Koninklijke Philips NV trades at $26.45 (market cap $25.47B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and Koninklijke Philips NV pays a 3.89% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PHG | |
|---|---|---|
Market Cap | $16.46B | $25.47B |
Sector | Health | Health |
52-Week High | $90.17 | $32.91 |
52-Week Low | $44.81 | $24.11 |
Enterprise Value | $18.02B | $31.74B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
PHG trades at $27.34, down 0.22% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operating cash flow of $1.17B. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships demonstrate innovation momentum.
The stock presents a mixed outlook with 41% analyst buy ratings but bearish technical indicators. Key opportunities include AI healthcare adoption and margin expansion, while risks involve competitive pressures and debt levels. Valuation appears reasonable with P/E of 24.01 and P/S of 1.31, but requires monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
